Concept, mechanisms and therapeutics of angiogenesis in cancer and other diseases

Journal of Pharmacy and Pharmacology

Volumn 55, Issue 8, 2003, Pages 1045-1053

  Pralhad, Tayade ^a   Madhusudan, Saraf ^a   Rajendrakumar, Kale ^a  

^a BOMBAY COLLEGE OF PHARMACY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2 NITROIMIDAZOLE; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOSTATIN; ANTINEOPLASTIC AGENT; CARBOPLATIN; COMBRESTATIN; COPPER; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLOOXYGENASE 2; ENDOSTATIN; INTEGRIN; KIN 841; MYC PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN; PROTEIN TYROSINE KINASE; RAPAMYCIN; SCH 221153; THALIDOMIDE; THROMBOPLASTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ARTHRALGIA; ASTHENIA; BIFIDOBACTERIUM; BLOOD VESSEL; BLOOD VESSEL FUNCTION; BLOOD VESSEL PERMEABILITY; CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CLINICAL TRIAL; COUGHING; DISEASE COURSE; DORMANCY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG MEGADOSE; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; GENE THERAPY; GLIOMA; HUMAN; LOW DRUG DOSE; MOLECULAR INTERACTION; MOLECULAR MECHANICS; NEUROTOXICITY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PERIPHERAL NEUROPATHY; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; BLOOD VESSELS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 0042025211     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357021819     Document Type: Review

References (77)

1. Alon, T., Hemo, I., Itin, A., Pe'er, J., Stone, J., Keshet, E. (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1: 1024-1028
2. Anderson, J. D., Hauser, S. D., McGarity, K. L., Bremer, M. E., Isakson, P. C., Gregory, S. A. (1996) Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J. Clin. Invest. 97: 2672-2679
3. Arbiser, J. L., Petros, J., Klafter, R., Govindajaran, B., McLaughlin, E. R., Brown, L. F., Cohen, C., Moses, M., Kilroy, S., Arnold, R. S., Lambeth, J. D. (2002) Reactive oxygen generated by Nox 1 triggers the angiogenic switch. Proc. Natl. Acad. Sci. USA 99: 715-720
4. Arora, N., Masood, R., Zheng, T., Cai, J., Smith, D. L., Gill, P. S. (1999) Vascular endothelial growth factors chimeric toxin is highly active against endothelial cells. Cancer Res. 59: 183-188
5. Baudino, T. A., McKay, C., Pendeville, S., Nilsson, J. A., Maclean, K. H., White, E. L., Davis, A. C., Ihle, J. N., Cleveland, J. L. (2002) c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev. 16: 2530-2543
6. Bikfalvi, A., Bicknell, R. (2002) Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. Trends Pharmacol. Sci. 23: 576-582
7. Bocci, G., Nicolaou, K. C., Kerbel, R. S. (2002) Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveals a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 62: 6938-6943
8. Boehm, T., Folkman, J., Browder, T., O'Reilly, M. S. (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404-407
9. Brem, S. S., Zagzag, D., Tsanaclis, A. M., Gately, S., Elkouby, M. P., Brien, S. E. (1990) Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. Am. J. Pathol. 137: 1121-1142
10. 3 for angiogenesis. Science 264: 569-571
11. Carmeliet, P. (1999) Controlling the cellular breaks. Nature 401: 657-658
12. Carmeliet, P. (2000) Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6: 389-395
13. Carmeliet, P., Jain, R. (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257
14. Carson-Walter, E. B. (2001) Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res. 61: 6649-6655
15. Chan, G., Boyle, J. O., Zhang, F., Yang, E.K., Sacks, P. G. (1999) Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 59: 991-994
16. 5 integrin receptor antagonist. Cancer Res. 61: 2232-2238
17. Cheresh, D. A., Berliner, S. A., Vicente, V., Ruggeri, Z. M. (1989) Recognition of distinct adhesive sites on fibrinogen by related integrins on platelets and endothelial cells. Cell 58: 945-953
18. Chiarugi, V., Magnelli, L., Gallo, O. (1998) Cox-2, iNOS and p53 as play-makers of tumor angiogenesis. Int. J. Mol. Med. 2: 715-719
19. Claesson-Welch, L., Welsh, M., Ito, N. (1998) Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc. Natl Acad. Sci. USA 95: 5579-5583
20. Coussens, L. M., Raymond, W. W., Bergers, G., Laig-Webster, M., Behrendtsen, O., Werb, Z., Caughey, G. H., Hanahan, D. (1999) Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 13: 1382-1397
21. D'Amato, R. J., Loughnan, M. S., Flynn, E. (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad. Sci. U S A 91: 4082-4085
22. Drake, M. J., Robson, W., Mehta, P., Schofield, I. M., Neal, D. E., Leung, H. Y. (2003) An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br. J. Cancer 88: 822-827
23. Featherstone , J., Griffiths, S. (2002) From the analyst's couch. Drugs that target angiogenesis. Nat. Rev. Drug Discov. 1: 413-414
24. Fidler, I. J. (1995) Modulation of the organ microenvironment for treatment of cancer metastasis. J. Natl Cancer Inst. 87: 1588-1592
25. Folkman, J. (1996) Tumor angiogenesis and tissue factor. Nat. Med. 2: 167-168
26. Folkman, J. (1999) Angiogenesis research: From laboratory to clinic. Forum 9: 59-62
27. Folkman, J., Shing, Y. (1992) Angiogenesis. J. Biol. Chem. 267: 10931-10934
28. Fotsis, T., Zhang, Y., Pepper, M. S. (1994) The endogenous estrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumor growth. Nature 368: 237-239
29. Fridovich, I. (1978) The biology of oxygen radicals. Science 201: 875-880.
30. 5 in ocular neovascular diseases. Proc. Natl Acad. Sci. USA 93: 9764-9769
31. Friedlander, M., Brooks, P. C., Shaffer, R. W., Kincaid, C. M., Varner, J. A., Cheresh, D. A. (1995b) Definition of two angiogenic pathways by distinct αv integrins. Science 270: 1500-1502
32. Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E. C. (1998) Tumor induction of VEGF promoter activity in stromal cells. Cell 94: 715-725
33. Gately, S., Twardowski, P., Stack, M. S. (1997) The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc. Natl Acad. Sci. USA 94: 10868-10872
34. Giancotti, F. G., Ruoslahti, E. (1999) Integrin signaling. Science 285: 1028-1032
35. Gille, H., Kowalsaki, J., Li, N., LrCouter, J., Moffat, B., Zioncheck, T. F., Pelletier, N., Ferrara, N. (2001) Analysis of biological effects and signaling properties of Flt-1 (VEGFR) and KDR (VEGFR-2). A reassessment using a novel receptor specific vascular endothelial growth factor mutants. J. Biol. Chem. 276: 3222-3230
36. Goddard, D. H., Grossman, S. L., Newton, R., Clark, M. A., Bonalaski, J. S. (1992) Regulation of synovial cell growth: Basic fibroblast growth factor synergizes with interleukin 1 beta stimulating phospholipase A2 enzyme activity, phospholipase A2 activating protein production and release of prostaglandin E2 by rheumatoid arthritis synovial cells in culture. Cytokine 4: 377-384
37. Gohoni, T. (1999) Tumor host interactions in the gallbladder suppress distal angiogenesis and tumor growth: Involvement of transforming growth factor beta 1. Nat. Med. 5: 1203-1208
38. Guba, M., Breitenbuch, P. V., Steinbauer, M. (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis involvement of vascular endothelial growth factor. Nat. Med. 8: 128-135
39. Gullino, P. M. (1978) Angiogenesis and oncogenesis. J. Natl Cancer Inst. 61: 639-643
40. Hansen, S., Overgaard, J., Rose, C., Knoop, A., Laenkholm, A., Andersen, J., Sorensen, F. B., Andreasen, P. A. (2003) Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type I in breast cancer patients. Br. J. Cancer 88: 102-108
41. Hartford, A. C., Gohongi, T., Fukumura, D., Jain, R. K. (2000) Irradiation of primary tumor, unlike surgical removal, enhances angiogenesis suppression at a distal site: Potential role of host tumor interactions. Cancer Res. 60: 2128-2131
42. Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., Jain, R. K. (1998) Regulation of transport pathways in tumour vessels, role of tumour type and microenvironment. Proc. Natl Acad. Sci. USA 95: 4607-4612
43. Hu, G. F. (1998) Copper stimulates proliferation of human endothelial cells under culture. J. Cell Biochem. 69: 326-335
44. Huang, P., Feng, L., Oldham, E. A. (2000) Superoxide dismutase as a target for selective killing of cancer cells. Nature 407: 390-395
45. Jackson, J. R., Seed, M. P., Kircher, C. H., Willoughby, D. A., Winkler, J. D. (1997) The codependence of angiogenesis and chronic inflammation. FASEB J. 11: 457-465
46. Kage, K., Fugita, N., Oh-hara, T., Ogata, E., Fugita, T. (1999) Basic fibroblast growth factor induces cyclooxygenase-2 expression in endothelial cells derived from bone. Biochem. Biophys. Res. Commun. 254: 259-263
47. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., Ferrara, N. (1993) Inhibition of vascular endothelial growth factors induced angiogenesis suppresses tumor growth in vivo. Nature 362: 841-844
48. Kisker, O., Becker, C. M., Prox, D., Fannon, M., D'Amato, R., Flynn, E., Fogler, W. E., Sim, B. K., Allred, E. N., Pirie-Shepherd, S. R., Folkman, J. (2001) Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 61: 7669-7674
49. Kuo, C. J., Farnebo, F., Yu, E. Y. (2001) Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc. Natl Acad. Sci. USA 98: 4605-4610
50. Liu, J., Razani, B., Tang, S. (1999) Angiogenesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells. Angiogenesis inhibitors block vascular endothelial growth factor-induced down-regulation of caveolin-1. J. Biol. Chem. 274: 15 781-15 785
51. Lyden, D. (2001) Impaired recruitment of bone marrow derived endothelial and haematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7: 1194-1201
52. Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S. (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60
53. Marikovsky, M., Nevo, N., Vadai, E., Harris, C. C. (2002) Cu/Zn superoxide dismutase plays a role in angiogenesis. Int. J. Cancer 97: 34-41
54. McAuslan, B., Reilly, W. (1980) Endothelial cell phagokinesis in response to specific metal ions. Exp. Cell Res. 130: 147-157
55. Molema, G. (2002) Tumor vasculature directed drug targeting: Applying new technologies and knowledge to the development of clinically relevant therapies. Pharm. Res. 19: 1251-1258
56. Moser, T. L., Stack, M. S., Asplin, I. (1999) Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl Acad. Sci. USA 96: 2811-2816
57. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., Folkman, J. (1994) Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328
58. O'Reilly, M. S., Holmgren, L., Chen, C. (1996) Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2: 689-692
59. O'Reilly, M. S., Boehm, T., Shing, Y. (1997) Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285
60. Oslon, T. A., Mohanraj, D., Roy, S., Ramakrishnan, S. (1997) Targeting the tumor vasculature: Inhibition of tumor growth by vascular endothelial growth factor-toxin conjugate. Int. J. Cancer 73: 865-887
61. Pinedo, H. M., Verheul, H. M., D'Amato, R. J., Folkman, J. (1998) Involvement of platelets in tumor angiogenesis? Lancet 352: 1775-1777
62. Ruoslahti, E. (2002) Specialization of tumour vasculature. Nat. Cancer Rev. 2: 83-90
63. Sano, H., Kawahito, Y., Wilder, R. L., Hashiramato, A., Mukai, S., Asai, K. (1995) Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 55: 3785-3789
64. Sasaki, E., Pai, R., Halter, F., Komurasaki, T., Arakawa, T., Kobayashi, K., Kuroki, T., Tarnawski, A. S. (1998) Induction of cyclooxygenase-2 in a rat gastric epithelial cell line by epiregulin and basic fibroblast growth factor. J. Clin. Gastroentrol. 27 (Suppl. 1): S21-S27
65. Seljelid, R., Jozefowski, S., Sveinbjornsson, B. (1999) Tumor stroma. Anticancer Res. 19: 4809-4822
66. Shewiki, D., Itin, A., Soffer, D. (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845
67. Shimamura, M., Nagasawa, H., Ashino, H., Yamamoto, T., Hazato, Y., Hori, H., Inayama, S. (2003) A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumor-specific angiogenesis by blocking production of angiogenic factors. Br. J. Cancer 88: 307-313
68. Silverman, K. J., Lund, D. P., Zetter, B. R., Lainey, L. L., Shahood, J. A., Freiman, D. G., Folkman, J., Barger, A. C. (1988) Angiogenic activity of adipose tissue. Biochem. Biophys. Res. Commun. 153: 347-352
69. Sim, B. K., O'Reilly, M. S., Liang, H. (1997) A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res. 57: 1329-1334
70. 3 targeted magnetic resonance imaging. Nat. Med. 4: 623-626
71. St Croix, B., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., Kinzler, K. W. (2000) Genes expressed in human tumor endothelium. Science 289: 1197-1202
72. Stack, M. S., Gately, S., Bafetti, L. M. (1999) Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem. J. 340: 77-84
73. Tucker, O. N., Dannenberg, A. J., Yang, E. K., Zhang, F. (1999) Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 59: 987-990
74. Willis, M. C., Collins, B. D., Zhang, T. (1998) Liposome-anchored vascular endothelial growth factor aptamers. Bioconjug. Chem. 9: 573-582
75. Xi, L., Geng-Feng, F., Yang-Rong, F., Wen-Hua, L., Xin-Juan, L., Jian-Jun, W., Gen-Xing, X (2003) Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: Selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther. 10: 105-111
76. Ylikorkala, A., Rossi, D. J., Korsisaari, N., Luukko, K., Alitalo, K., Henkemeyer, M., Makela, T. P. (2001) Vascular abnormalities and degeneration of VEGF in Lkb1-deficient mice. Science 293: 1323-1326
77. Ziche, M., Jones, J., Gullino, P. M. (1982) Role of prostaglandin E1 and copper in angiogenesis. J. Natl Cancer Inst. 69: 475-482